金斯瑞生物科技：传奇宣布于2025年ASH年会上公布报告

Core Viewpoint - Kingsray Biotechnology (01548) announced that its affiliate Legend Biotech Corporation will present long-term follow-up clinical and translational research data from the CARTITUDE-1 and CARTITUDE-4 studies on CARVYKTI (cilta-cel) for patients with relapsed or refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) annual meeting on December 6, 2025 [1] Group 1 - Legend Biotech will showcase the latest results from the Phase III study CARTITUDE-4, along with six posters demonstrating the durability of response data for CARVYKTI across different subgroups and real-world study results [1] - The presentation will also include initial human trial data for the dual-target allogeneic CAR-T candidate product LUCAR-G39D [1]